Puerarin affects bone biomarkers in the serum of rats with intrauterine growth restriction  by Juncao, Chen et al.
TOPIC
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 2 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2016 April 15; 36(2): 211-216
info@journaltcm.com ISSN 0255-2922
© 2016 JTCM. All rights reserved.
EXPERIMENTAL STUDY
Puerarin affects bone biomarkers in the serum of rats with intrauter-
ine growth restriction
Chen Juncao, Chen Pingyang, Qi Huaxue, Huang Danhong
aa
Chen Juncao, Chen Pingyang, Qi Huaxue, Huang Dan-
hong, Neonatal Division, The Second Xiangya Hospital, Cen-
tral South University, Changsha 410011, China
Supported by the Administration of Traditional Chinese
Medicine of Hunan Province (Effect of Puerarin on Low Birth
Weight Associated with Adulated Osteoporosis, No. 201110)
Correspondence to: Prof. Chen Pingyang, Neonatal Divi-
sion, The Second Xiangya Hospital, Central South University,
Changsha 410011, China. wycpyfu@163.com
Telephone: +86-13637480919
Accepted: August 17, 2015
Abstract
OBJECTIVE: To investigate serum bone biomarkers
in rats with intrauterine growth restriction (IUGR) in
order to determine the effects of puerarin on bone
metabolism.
METHODS: A rat model of IUGR was induced using
a low protein diet during pregnancy. The offspring
were given puerarin or an identical volume of sa-
line via subcutaneous abdominal injection. All rats
were studied at 1, 3, and 8 weeks of age. Serum bio-
markers of bone formation, including insulin-like
growth factor-1 (IGF-1), bone-specific alkaline phos-
phatase (BALP), osteocalcin (OC), osteoprotegerin
(OPG), receptor-activator of nuclear factor-κB li-
gand (RANKL), as well as blood levels of calcium
and phosphorus were measured.
RESULTS: Serum BALP, OPG, IGF-1, and OC levels,
as well as the OPG/RANKL ratio, were lower in the
IUGR group compared with the control group at 1
week of age (P = 0.024, 0.011, 0.014, 0.004, and
0.002, respectively). At 3 weeks of age, the serum
BALP and OC levels were higher in the protein-re-
stricted group compared with the control group
(P = 0.003 and 0.001, respectively). A comparison
between the IUGR plus puerarin intervention
group and the IUGR group revealed differences in
the levels of BALP and IGF-1 at 3 weeks of age (P =
0.008 and 0.003, respectively). In addition, serum
OPG and OC levels and the OPG/RANKL ratio were
higher at 8 weeks of age (P = 0.044, 0.007, and
0.016, respectively). No differences in serum calci-
um and phosphorus levels were observed among
the three groups.
CONCLUSION: Our study demonstrates that the
bone microenvironment of the fetus can be altered
by a low protein maternal diet and that puerarin
can reverse these effects. These results indicate
that the nutritional environment plays an impor-
tant role in early skeletal development and that the
bone turnover of IUGR rats can be altered by puera-
rin treatment.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
In humans, the development of the fetus can have ma-
jor influences on the adult phenotype. A good example
of this phenomenon is seen in intrauterine growth re-
striction (IUGR), which can be defined as when the es-
timated fetal weight (EFW) is below the 10th percen-
tile of healthy fetus of the same gestational age. Causes
of IUGR include malnutrition, placental insufficiency,
and congenital anomalies. IUGR affects approximately
10%-15% of pregnant women.1 Fetuses with IUGR
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have a higher risk of perinatal morbidity, mortality and
long-term sequelae, including osteoporosis, obesity, in-
sulin resistance, hypertension, and brain injury.
Bone formation requires adequate supplies of energy,
amino acids, minerals, and vitamins. Some studies
have indicated that the intrauterine environment plays
an important role in skeletal development.2 In recent
years, many studies have reported that protein deficien-
cies during pregnancy have an adverse effect on bone
growth. Mehta et al 3 reported that maternal protein re-
striction during pregnancy results in reduced bone area
and bone mineral content (BMC). Lanham et al 4 also
demonstrated that a low protein maternal diet affects
the bone structure of female offspring when they reach
an elderly age using micro-computed tomography (mi-
cro-CT) and mechanical testing. Thus, bone growth
may have been affected by IUGR, which was induced
by protein deficiency during pregnancy.
In recent years, estrogen replacement therapy has been
considered an effective approach for preventing age-re-
lated bone loss in females.5 Puerarin [4H-1-benzopy-
ran-4-one,8-b-D-glucopyranosyl-7-hydroxy-3-(4-hy-
droxy-phenyl)] is a major phytoestrogen, isolated from
Gegen (Radix Puerariae Lobatae), which binds to estro-
gen receptors and has weak estrogenic activity. Wang et
al.6 demonstrated that puerarin reduces the loss of
bone density that occurs in ovariectomized mice. Wong
et al 7 also demonstrated that puerarin induces local in-
creases in new bone formation in a collagen matrix.
This study was based on the hypothesis that serum
bone biomarkers may differ between rats with IUGR
and healthy controls. We further hypothesized that pu-
erarin treatment could promote recovery of serum
bone biomarkers to normal levels. Serum levels of insu-
lin-like growth factor-1 (IGF-1), osteocalcin (OC),
bone specific alkaline phosphatase (BALP), osteoprote-
gerin (OPG), and receptor-activator of nuclear factor
kappa beta ligand (RANKL) were measured to deter-
mine the association between these biomarkers and IU-
GR. In addition, circulating levels of calcium and phos-
phorus were evaluated.
MATERIALS ANDMETHODS
Animals and treatments
All experimental designs and procedures received ap-
proval by the Animal Ethics Committee of Central
South University (Changsha, China). Specific patho-
gen free -grade Sprague-Dawley rats [18 females, 9
males; 3 months of age, weighing (220 ± 20) g], pur-
chased from the Experimental Animal Center of Cen-
tral South University [certificate of quality No. SCXK
(xiang) 2009-0012], were housed individually at 25 ℃,
with a 12∶12 h light-dark cycle. Successful mating was
confirmed after observing sperm in a vaginal smear;
the day of successful mating day was used as day zero
of gestation. After gestational day 0, pregnant dams
were housed individually and were randomly allocated
to either a normal protein diet containing 21% protein
(w/w), for the control group, or a low protein diet con-
taining 10% protein (w/w) for both the IUGR and the
IUGR plus puerarin intervention groups; both diets
had the same caloric value.4,8 Offspring of both the IU-
GR and IUGR plus puerarin intervention groups were
randomly divided into two subgroups using a random
number table. One group received 50 mg·kg－1·d－1 of
puerarin (Tianjin Pharmaceutical Group Co., Xin-
zheng Ltd., Xinzheng, Henan, China) via subcutane-
ous abdominal injection for 1 week, whereas the other
group received an injection of the same volume of sa-
line. Experimental samples were harvested after 1, 3,
and 8 weeks. Blood was collected in pyrogen-free tubes
after centrifugation. The supernatants from the serum
samples were frozen at－80 °C until the time of the as-
say.
Plasma OPG levels were measured using an en-
zyme-linked immunosorbent assay (ELISA;
SEA108Ra, Cloud-clone Co., Houston, TX, USA)
with a detection range of 0.156-10 ng/mL and a sensi-
tivity of 0.053 ng/mL. Plasma IGF-1 levels were also
measured using an ELISA (SEA050Ra, Cloud-clone
Co., Houston, TX, USA) with a detection range of
78.125-5000 pg/mL and a sensitivity of 30 pg/ml. Plas-
ma osteocalcin levels were measured using an ELISA
(SEA 471Ra, Cloud-clone Co., Houston, TX, USA)
with a detection range of 15.625-1000 pg/mL and a
sensitivity of 6.3 ng/mL. Plasma BALP levels were mea-
sured using an ELISA (SEB 091Ra, Cloud-clone Co.,
Houston, TX, USA) with a detection range of
0.781-50 ng/mL and a sensitivity of 0.28 ng/ml. Plas-
ma RANKL levels were measured using an ELISA
(SEA855Ra, Cloud-clone Co., Houston, TX, USA)
with a detection range of 15.625-1000 ng/mL and a
sensitivity of 5.3 ng/mL. Serum calcium and phospho-
rus levels were measured using the ARCHITECT
c8000 system (Abbott Co., Chicago, IL, USA).
Statistical analysis
The data are represented as the mean ± standard devia-
tion ( xˉ ± s). Multiple samples were compared using
analysis of variance. Several sets of multiple samples
were analyzed via several pairwise comparisons using
the analysis of variance least significant difference meth-
od. Sample rates were compared using the χ2 test. All
computations were performed using SPSS 17.0 soft-
ware (SPSS Inc., St. Louis, MO, USA). Differences
with P < 0.05 were considered statistically significant.
RESULTS
The birth weights of offspring whose mothers were fed
a restricted protein diet (i.e., the IUGR and IUGR
plus puerarin intervention groups) met the criteria for
IUGR and were significantly lower than those of the
control group (P > 0.001). After 1 week, the body
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weights of rats in both the IUGR and the IUGR plus
puerarin intervention groups were also lower than that
of the control group (P = 0.001 and P = 0.002, respec-
tively). After 3 weeks, the body weights of rats in the
IUGR plus puerarin intervention group increased, al-
though they were not significantly different from that
of the IUGR group (P = 0.081). After 8 weeks, the
body weights of rats in the IUGR plus puerarin inter-
vention group were significantly higher than that of
the IUGR group (P = 0.032) (Figure 1).
The values for each bone marker examined are present-
ed in Tables 1 and 2. A comparison between both the
IUGR and control groups revealed that serum levels of
the bone biomarkers BALP, OPG, OPG/RANKL,
IGF-1, and OC were significantly lower than those of
the control group at 1 week of age (P = 0.024, 0.011,
0.002, 0.014, and 0.004, respectively). After 3 weeks,
serum BALP and OC levels in the IUGR group were
significantly higher than those of the control group
(P = 0.003 and 0.001, respectively). No significant dif-
ferences in serum BALP, OPG, OPG/RANKL, IGF-1,
or OC levels were observed between the two groups at
8 weeks of age (P > 0.05).
At 3 weeks of age, serum BALP and IGF-1 levels were
significantly higher in IUGR rats administered puera-
rin compared with IUGR rats that did not receive in-
tervention (P = 0.008 and 0.003, respectively). At 8
weeks of age, serum OPG and OC levels, as well as the
OPG/RANKL ratios of rats administered puerarin
were higher than those of IUGR group rats, while the
levels of BALP and IGF-1 continued to increase in IU-
GR groups.
At 1 week of age, the IGF-1 levels of both the IUGR
and the IUGR plus puerarin intervention groups were
significantly lower than those of the control group (P =
0.001 and 0.002, respectively). At 3 weeks of age, the
IGF-1 levels of the IUGR plus puerarin intervention
group significantly increased more than those of both
the control and IUGR groups (P = 0.003 and 0.010,
respectively). However, at 8 weeks of age, there were
no differences observed among the three groups (P =
0.656).
At 1 week of age, the OC levels of the control group
were also significantly higher than those of both the
IUGR and the IUGR plus puerarin intervention
groups (P = 0.004 and 0.037, respectively). However,
at 3 weeks of age, the OC levels of the control group
were significantly lower than those of both the IUGR
and IUGR plus puerarin intervention groups (P =
0.001 and 0.003, respectively). The OC levels of the
IUGR plus puerarin intervention group continued to
increase and were the highest among the three groups
at 8 weeks of age. The differences observed between
comparisons of the IUGR plus puerarin intervention
group with the control group and the IUGR group
were statistically significant (P = 0.013 and 0.007, re-
spectively).
The BALP levels of the control group were higher than
Figure 1 Line chart of the body weights of the three groups
at birth, and at 1, 3 and 8 weeks of age
Control group was treated with only physiological saline;
whereas both the IUGR and IUGR plus puerarin groups, who
were offspring of mothers administered low protein diets
during pregnancy, were treated with physiological saline or
puerarin, respectively. IUGR: intrauterine growth restriction.
aP < 0.05, control group vs IUGR group; bP < 0.05, IUGR group
vs IUGR plus puerarin intervention groups.
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Time point
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IUGR plus puerarin intervention
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6
6
6
6
6
6
6
6
6
IGF-1
(μg/L)
7.91±0.32
6.36±0.19a
6.73±0.89
7.20±0.53
7.59±0.22
8.95±0.52b
7.29±0.29
7.69±0.67
7.10±1.03
Osteocalcin
(ng/L)
413.98±6.77
343.77±23.85a
371.87±22.42
325.45±16.65
396.84±13.20a
386.34±17.08
372.20±39.67
360.27±1.92
443.61±17.75b
BALP
(ng/L)
3.21±0.35
2.58±0.19a
2.61±0.15b
3.25±0.28
4.12±0.22a
3.95±0.44
3.59±0.15
3.98±0.04a
3.63±0.15b
OPG
(ng/L)
549.77±26.42
470.32±8.42a
439.80±58.22
548.78±39.55
464.57±44.64
505.98±58.21
515.10±45.83
472.85±47.04
553.18±14.02b
Notes: control group was treated with only physiological saline; whereas both the IUGR and IUGR plus puerarin groups, who were off-
spring of mothers administered low protein diets during pregnancy, were treated with physiological saline or puerarin, respectively. IUGR:
intrauterine growth restriction; IGF-1: insulin-like growth factor-1; BALP: bone-specific alkaline phosphatase; OPG: osteoprotegerin. aP <
0.05, vs the control group; bP < 0.05, vs the IUGR group.
Table 1 Serum levels of bone markers from 1-, 3- and 8-week-old mice from all the three groups (n = 6, xˉ ± s)
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those of the IUGR and the IUGR plus puerarin inter-
vention groups (P = 0.020 and 0.024, respectively) at
1 week of age; however, they were significantly elevated
in both the IUGR and the IUGR plus puerarin inter-
vention groups at 3 weeks of age, but decreased again
at 8 weeks.
The OPG levels of all groups exhibited a similar pat-
tern to that observed for IGF-1. At 1 week of age, the
OPG levels of both the IUGR and the IUGR plus pu-
erarin intervention groups were significantly lower
than those of the control group (P = 0.040 and 0.011,
respectively). At 3 weeks of age, the OPG levels of the
IUGR plus puerarin intervention group were elevated;
the OPG levels of the IUGR plus puerarin interven-
tion group were significantly higher than those of the
IUGR group at 8 weeks of ages (P = 0.044).
The RANKL levels of the groups exhibited a pattern
that was opposite to that observed for OPG levels,
with the levels of the control group being lower than
those of both the IUGR and the IUGR plus puerarin
intervention groups (P = 0.019 and 0.015, respective-
ly). At 3 weeks of age, the RANKL levels of the IUGR
plus puerarin intervention group decreased significant-
ly. The RANKL levels of the IUGR plus puerarin inter-
vention group were lower than those of the IUGR
group at 3 and 8 weeks of age (P = 0.006 and 0.016,
respectively).
At 1 week of age, the OPG / RANKL ratios of the IU-
GR group and the IUGR plus puerarin intervention
group were lower than that of the control group (P =
0.001 and 0.002, respectively). At 3 weeks of age, the
OPG/RANKL ratio of the IUGR plus puerarin inter-
vention group was significantly higher than those of
both the control and IUGR groups (P = 0.003 and
0.010, respectively). However, at 8 weeks of age, there
were no significant differences observed among the
three groups (P > 0.05).
Comparisons among the three groups revealed no sig-
nificant differences in serum calcium and phosphorus
levels (P > 0.05).
DISCUSSION
This study demonstrated that the bone microenviron-
ment of offspring can be altered by a low protein ma-
ternal diet during pregnancy and that puerarin can re-
verse these effects. Maternal nutrition during pregnan-
cy not only affects fetal growth but also has long-term
effects on the growth and development of the child, in-
cluding their bones. Low birth weight is one of the
most direct manifestations of IUGR. Birth weight has
been demonstrated to be a predictor of adult bone
mass and skeletal size.9 Thus, IUGR induced by poor
maternal nutrition during pregnancy could affect adult
bone mass and skeletal size.
Maternal malnutrition during pregnancy affects
bone growth
The growth hormone (GH) / IGF-1 axis is a key endo-
crine pathway. In the blood, insulin-like growth factors
(IGFs) bind to IGF-binding proteins (IGFBPs),which
determines the bioavailability of these factors and regu-
lates the interaction between IGFs and insulin-like
growth factor-1 receptor (IGF-1R).10 Studies in animal
models and in humans established critical roles for
IGFs in skeletal growth and development. Bikle et al 11
reported that Igf1-/- mice exhibit a 24% reduction in
cortical bone size and a shortened femoral length. Hu-
man patients with IGF1 gene deletions have also been
identified, with those having homozygous IGF1 gene
deletions exhibiting growth retardation (i.e., short stat-
ure), reduced bone size, and reduced vertebral bone
mineral density.12,13 The results of our study are consis-
tent with these previous findings.
Serum OC levels have been widely used as a biomarker
of bone turnover and bone formation.14 Previous stud-
ies have evaluated the potential role of OC as a predic-
tor and surrogate marker of fracture or osteoporosis.15
Studies indicated that bone formation was decreased in
patients with IUGR, which was reflected by OC con-
Time
point
1 week
3 weeks
8 weeks
Group
Control
IUGR
IUGR plus puerarin intervention
Control
IUGR
IUGR plus puerarin intervention
Control
IUGR
IUGR plus puerarin intervention
n
6
6
6
6
6
6
6
6
6
RANKL
(pmol/L)
175.09±10.63
201.34±7.24a
202.84±11.87
185.17±10.10
191.24±3.02
165.31±7.95b
176.02±9.20
191.24±3.24a
170.67±8.47b
OPG/RANKL
3.14±0.08
2.34±0.11a
2.17±0.32
2.97±0.34
2.43±0.26
3.08±0.49
2.93±0.26
2.48±0.28
3.25±0.16b
Blood calcium
(mmol/L)
2.40±0.27
2.48±0.18
2.36±0.20
2.60±0.14
2.50±0.06
2.57±0.03
2.47±0.16
2.49±0.09
2.57±0.05
Blood phosphorus
(mmol/L)
4.19±0.64
4.44±1.20
4.31±1.04
3.10±0.41
3.20±0.12
2.94±0.16
2.80±0.49
2.87±0.28
2.62±0.33
Table 2 Serum levels of bone markers and OPG/RANKL ratios from 1-, 3-, and 8-week-old mice from all three groups ( xˉ ± s)
Notes: control group was treated with only physiological saline; whereas both the IUGR and IUGR plus puerarin groups, who were off-
spring of mothers administered low protein diets during pregnancy, were treated with physiological saline or puerarin, respectively. IUGR:
Intrauterine growth restriction; OPG: osteoprotegerin; RANKL: receptor-activator of nuclear factor-κB ligand. aP < 0.05, control group vs
IUGR group. bP < 0.05, IUGR group vs IUGR plus puerarin intervention group.
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centrations in the cord blood being 20% lower than
those of age- or weight-matched newborns.16 In our
study, the OC levels of the IUGR group were lower
than those of the control group (P = 0.004).
During the perinatal period, BALP is a reliable marker
of bone formation.17 An increase in liver ALP typically
requires increased hepatic lipid production. Protein re-
striction during pregnancy affects fetal liver lipid me-
tabolism.18 Lipid metabolism may be influenced by a
low protein diet in animal models, which suggests that
BALP levels of the IUGR group would be lower than
those of the control group. Briana et al 13 also reported
significant differences in BALP levels between the con-
trol and IUGR groups (P < 0.001).
The OPG/RANK/RANKL signaling pathway is a criti-
cal regulatory pathway that maintains a balance be-
tween the activity of osteoblasts and osteoclasts that
prevents bone loss and ensures normal bone turnover.19
Hossein et al 20 demonstrated the positive effects of fo-
lic acid supplementation during pregnancy on both ma-
ternal and fetal markers of bone turnover (i.e. OPG,
RANKL, and OC). This study demonstrated that the
RANKL/RANK/OPG system might play an important
role in bone formation during pregnancy. Our results
indicated that the levels of OPG and the OPG/
RANKL ratio of the IUGR group were lower than
those of the control group, thus indicating that IUGR
affects bone formation. Tenta et al 21 also demonstrated
that newborns with IUGR exhibited lower RANKL
values and higher OPG / RANKL ratios, while new-
borns that were large for their gestational age (LGA)
had higher RANK levels compared with healthy con-
trols (P = 0.036 and 0.044, respectively). This result
was similar those obtained in our study.
IUGR infants who receive sufficient nutrition postna-
tally appear to catch up in growth through accelerated
bone formation. In our study, at 3 weeks of age, the se-
rum levels of BALP and OC (P = 0.003 and 0.001, re-
spectively) of the IUGR group were significantly high-
er than those of the control group. No significant dif-
ferences were found the in the levels of BALP, OPG,
OPG/RANKL, IGF-1, or OC between the two groups
at 8 weeks of age (P > 0.05).
The diet of the IUGR group in our study was primari-
ly protein restricted, without any limitations in vita-
min, calcium, or phosphorus. Thus, the calcium and
phosphorus supply provided in this study should have
been sufficient for the rats. Indeed, in our cohort
study, serum calcium and phosphorus concentrations
were similar between IUGR cases and the control
group. In a clinical study, Briana et al 13 also revealed
that the level of calcium remained unchanged in IUGR
newborns.
Puerarin-induced changes in bone growth and
turnover markers in IUGR individuals
Puerarin has an analogous structure to that of genis-
tein. Phytoestrogens are plant-derived non-steroidal
compounds that bind to estrogen receptors (ERs) and
have estrogen-like activities.22 In recent years, an in-
creasing number of studies have confirmed that puera-
rin has weak estrogenic activity, including the induc-
tion of bone formation and other bone-protective ef-
fects; however, its mechanism of action on bone re-
mains unclear. A number of researchers have proposed
that puerarin affects bone through ERs, with effects
similar to those of 17-β-estradiol. An et al 23 proposed
that the osteogenic effects of phytoestrogens are based
on their ER-mediated and/or enzyme-inhibiting ef-
fects. ER-mediated activity was proposed to occur via
the preferential binding of phytoestrogens to ER-β,
which acts as a dominant-negative regulator of estro-
gen signaling.24 However, Liang et al 25 suggested that
puerarin might play a protective role in diabetic osteo-
porosis via the reduction of caspase-3 expression.
Previous studies demonstrated that estrogens also play
an essential role in pubertal growth via the GH/IGF-I
axis.26 Indeed, estrogens stimulate GH secretion, which
induces hepatic synthesis of IGF-I.27 In our study, after
puerarin administration, the level of IGF-1 increased.
We propose that puerarin has estrogen-like activity
that may stimulate GH secretion, which subsequently
increases IGF-1 secretion.
Oral estrogen treatment has been previously associated
with weight gain in patients.28 In our study, after the
administration of puerarin, body weight also signifi-
cantly increased. This effect might be associated with
increased hepatic lipid production, which could ac-
count for the increased BALP levels in the IUGR
group after puerarin treatment.
OC is produced by osteoblasts during bone formation.
Circulating OC levels are likely to include molecules
derived from bone resorption, when OC embedded in
the bone matrix is released.29 We propose that accelerat-
ed bone formation induced by puerarin increased the
levels of OC in our study.
The RANKL/RANK/OPG system is regulated by
many osteotropic hormones and cytokines. A previous
study demonstrated that transforming growth factor-β
(TGF-β) and estrogen could activate this system.30 In
addition, Rubin et al 31 found that IGF-I increased
RANKL expression and decreased OPG expression in
mouse stromal cells in vitro. In our study, the levels of
OPG and the OPG / RANKL ratio increased after pu-
erarin administration. Thus, we propose that puerarin
has estrogen-like activity, which stimulates OPG secre-
tion and reduces RANKL secretion.
In this study, we identified a number of bone markers
that were affected in IUGR rats. Although the ob-
served changes were small, they were consistent and sig-
nificant. Future studies are needed to evaluate the
mechanism that underlies changes in bone turnover
markers during infancy.
Our study demonstrated that rats with IUGR have al-
tered bone metabolism. Puerarin promotes the recov-
ery of bone metabolic markers to normal levels, sug-
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gesting that it promotes bone turnover. Further re-
search, particularly large-scale surveys, are needed to in-
vestigate the expression of these bone biomarkers in
newborns with IUGR and to gain an improved under-
standing of the mechanism of bone formation.
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